Abstract: Described herein is a hair care composition having from about 0.2% to about 10% of one or more surfactant soluble active agents, from about 1% to about 10% of one or more viscosity reducing agents having a partition dispersion coefficient of from about 0.05 to about 2.0, from about 16% to about 40% of one or more anionic surfactants, and from about 40% to about 83% of a carrier. The hair care composition has a liquid phase kinematic viscosity, measured at 40 degrees Celsius, of from about 10 cSt to about 1000 cSt.

Abstract: The present invention relates to a fermented vegetable oil, to a method for preparing the oil, and to a composition including the oil. More particularly, the present invention relates to a technique for providing a fermented vegetable oil having the effects of enhancing emulsion stability due to water retention ability, improving texture and flavor, and enhancing moisturization.

Abstract: The invention provides a method for obtaining a composition, the method comprising the steps of: (a) combining an amount of an active agent with a carrier to provide a diluted formulation; (b) taking an amount of diluted formulation and combining it with carrier to provide a more diluted formulation; (c) taking an amount of the more diluted formulation and combining it with carrier to provide a yet more diluted formulation, (d) repeatedly carrying out the step of taking the most diluted version of the formulation and combining an amount of said formulation with carrier, until a final formulation is obtained where the concentration of the active agent is less than 1×10?10 ppm; wherein the steps of (a) to (d), in which active agent is combined with carrier, are carried out over a period of time of an hour or more; and then (e) combining an amount of the final formulation with one or more skin composition ingredients, to provide a skin composition where the concentration of the active agent is less than 1×10?11

Abstract: A regimen and kit for treating select facial or body surfaces to modulate the appearance of the desired volume on the treated surface.

Abstract: A lip treatment composition for creating a perceptible buzzing sensation when applied to mucosa membrane of a user. The composition has one or more base ingredients and at least one active ingredient comprising Zanthoxylum essential oil extracted in a liquid carbon dioxide process that induces a perceptible sensation reminiscent of electrical buzzing when applied to the mucosa membrane of the user. The Zanthoxylum essential oil could comprises between approximately 2.0000% and 4.0000% by weight of the composition and could comprise approximately 3.3000% by weight of the composition. The lip treatment composition can be formed under a process including heating the one or more base ingredients, adding the at least one active ingredient, and mixing the one or more base ingredients and the at least one active ingredient.

Abstract: The present invention is directed to treatment methods for a disease or condition, in a subject in need of such treatment, that provide alternatives to treatment by injection that give, relative to treatment by injection, improved treatment outcomes, 100% treatment compliance, reduced side effects, and rapid establishment and/or termination of substantial steady-state drug delivery. The method typically includes providing continuous delivery of a drug from an implanted osmotic delivery device, wherein substantial steady-state delivery of the drug at therapeutic concentrations is typically achieved within about 7 days or less after implantation of the osmotic delivery device in the subject and the substantial steady-state delivery of the drug from the osmotic delivery device is continuous over a period of at least about 3 months. In one embodiment, the present invention is directed to treatment of type 2 diabetes mellitus using incretin mimetics.

Abstract: This invention provides an effervescent solid form that dissolves in cold water quickly enough to not disappoint consumers yet not so quickly that the visual interest generated during the effervescent reaction is lost. This performance is achieved by forming effervescent particles that are dense enough to retard dissolution and small enough to not take too long to dissolve. The aim of this invention is to provide a beverage in solid effervescent form that takes between about 30 and about 120 seconds to dissolve in warm water. The granules may carry functional additives such as flavors, vitamins, minerals, sweeteners, colors and drugs. The granules may also be compounded of materials intended to provide relief from skin or topical discomfort, as in the form of a wash or bath additive. The granules may also be formulated to provide cleaning agents, such as ceramic cleaners and denture cleaners.

Abstract: An antimicrobial composition and methods of use are provided. The antimicrobial composition includes a water-soluble antimicrobial organosilane ammonium compound and a sugar. The composition may be in liquid, foam, ointment or gel form. The composition may include anti-inflammatory medications, alcohol and/or steroids. The antimicrobial composition may be used to treat eye infections in humans and animals. The antimicrobial composition may be applied directly to the surface of the eye. The antimicrobial composition may further be used to treat ocular related articles, including contact lenses, contact cases, instruments, pads and the like. The antimicrobial composition may be applied directly to the surface of the ocular related article during and/or after manufacture.

Abstract: Pharmaceutical compositions for intraocular injection are described, the compositions comprise therapeutically effective quantity of lyophilized preservative-free and sulfite-free epinephrine or adrenaline and a metal chelator. Methods for fabricating the compositions and using them for intraocular injections are also described.

Abstract: Disclosed herein are drug delivery devices and methods for the treatment of ocular disorders requiring targeted and controlled administration of a drug to an interior portion of the eye for reduction or prevention of symptoms of the disorder. In several embodiments, the devices are configured to release a pro-drug form of a drug into a target tissue site, wherein the pro-drug is converted to an active drug that yields a therapeutic effect. The use of the device and pro-drug form advantageously, in several embodiments, provide a stable drug composition that can yield a therapeutic effect over an extended time period.

Abstract: An improved method for manufacture of chewing gums containing active ingredient(s) that preserves the efficacy of the active ingredient(s) by avoiding exposure to high heat and extreme cold during milling that can otherwise degrade the active's efficacy. A chewing gum base is used, along with one or more therapeutically-active ingredients, one or more sweeteners (alcohol-based and/or natural), and one or more flavorings and optional flavor modifiers. The method generally comprises heating the gum base in ovens to melt the gum base. Separately, the active ingredient(s), sweeteners and flavorings are combined in a mixer. The melted gum base is added to the mixer and cools to produce a particulate mixture. As mixing continues the mass cools to room temperature and forms granular pieces. The granular pieces are ground into a powder at room temperature, mixed at room temperature with tableting excipients, and tableted. Several variations on the foregoing are also described.

Abstract: A method to form a dialysis composition includes determining for a patient a prescribed calcium concentration for a dialysis fluid to be administered to the patient. The determination is made based on a non-citrate containing calcium dialysis fluid. 0.5 to 3 mM citrate and 1 to 5 mM total calcium are introduced to the dialysis fluid. The total calcium results in a calcium concentration that is 0.1 to 0.2 mM per 1 mM citrate greater than the prescribed calcium concentration. 0 to 1.5 mM total magnesium is introduced to the dialysis fluid.

Abstract: The present disclosure provides compositions comprising a jasmonic acid derivative and a carrier, such as a liposome or cyclodextrin. Said compositions may be used for treating cancer.

Abstract: The present invention provides a hybrid biocompatible carrier (hybridosome) which comprises structural and bioactive elements originating from at least one biocompatible delivery module (BDM) and at least one engineered drug encapsulation module (EDEM) comprising at least one tunable fusogenic moiety. The invention further provides pharmaceutical compositions comprising said hybridosomes, processes for their manufacture, as well as pharmaceutical uses and pharmaceutical methods based thereon.

Abstract: Carrier particles in which at least 60% of the surface is coated with magnesium stearate are useful for preparing dry powder formulations for inhalation.

Abstract: The present disclosure provides a stable solid pharmaceutical dosage form for oral administration. The dosage form includes a substrate that forms at least one compartment and a drug content loaded into the compartment. The dosage form is so designed that the active pharmaceutical ingredient of the drug content is released in a controlled manner.

Abstract: Processes of preparing pharmaceutical compositions comprising 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid (Compound 1) in Form I and a solid dispersion comprising substantially amorphous N-(5-hydroxy-2,4-ditert-butyl-phenyl)-4-oxo-1H-quinoline-3-carboxamide (Compound 2), methods of treating, lessening the severity of or symptomatically treating CFTR mediated diseases, such as cystic fibrosis, methods of administering, and kits thereof are disclosed.

Abstract: The present disclosure relates to a taste-masking microcapsule composition. The composition comprises a core portion encapsulated by a shell portion. The core portion comprises an active pharmaceutical ingredient (API) and one or more excipients. The shell portion comprises a hydrophobic matrix and a pH-responsive material. The microcapsule compositions prevent API release at the more neutral pH levels in the oral cavity, but upon exposure to pH levels of the stomach, the pH-responsive material becomes soluble thereby permitting release of the API.

Abstract: Lipidated micro- or macroparticles are prepared by covalently linking a glycoprotein, typically collagen, with at least one lipid. An amino group in the glycoprotein is joined with a primary amine in the lipid. These particles can be used to encapsulate active ingredients, such as drugs.

Abstract: The invention refers to a pharmaceutical or nutraceutical composition, comprising a) a core, comprising a pharmaceutical or a nutraceutical active ingredient, b) an inner coating layer comprising one or more salts of alginic acid and c) an outer coating layer comprising one or more water-insoluble polymers or copolymers and one or more water-soluble polymers, selected from the group of water soluble celluloses, polyvinyl pyrrolidones or polyethylene glycols or any combinations thereof. wherein the ratio by weight of the amount of the one or more salts of alginic acid in the inner coating layer to the amount of the one or more water-insoluble polymers or copolymers in outer coating layer is from 0.6 to less than 2.5:1.

Abstract: The present disclosure generally relates to nanoparticles having about 0.2 to about 35 weight percent of a therapeutic agent; and about 10 to about 99 weight percent of biocompatible polymer such as a diblock poly(lactic) acid-poly(ethylene)glycol. Other aspects of the invention include methods of making such nanoparticles.

Abstract: CXCL12 polypeptide eluting matrices encapsulating at least one cell are described for use in the treatment of autoimmune disorders.

Abstract: Provided is an emedastine-containing tape preparation comprising a support film, and a pressure-sensitive adhesive layer laminated on the support film, wherein the pressure-sensitive adhesive layer comprises emedastine, a fumarate salt of an organic amine, and a pressure-sensitive adhesive.

Abstract: A method for enhancing neurological health and development in a subject involving administering to the subject a nutritional composition including no greater than about 7 g/100 kcal of a fat or lipid source; no greater than about 7 g/100 kcal of a protein or protein equivalent source; at least about 5 g/100 kcal of a carbohydrate; and at least about 9 mg/100 kcal of inositol, wherein the ratio of exogenous inositol to inherent inositol is at least 50:50.

Abstract: The use of tapentadol in the treatment of pain and/or pain chronification in a subject suffering from pain chronification and/or in the treatment of pain and inhibition of pain chronification in a subject suffering from pain and at risk of pain chronification, as well as the use of tapentadol for the treatment or inhibition of migraine.

Abstract: The present invention relates to the use of compositions comprising trans-clomiphene for treating men with hypogonadism. The invention is also directed to methods for treating males with hypogonadism.

Abstract: An improved local anesthetic solution with diminished bitter taste includes an anesthetic agent, an anesthetic solution vehicle, and a bitterness suppressant. The bitterness suppressant includes one or more compounds selected from the group consisting of: a sugar selected from the group consisting of monosaccharide sugars, disaccharide sugars, polysaccharide sugars, and combinations of the any of the foregoing; sweet-tasting compounds; acids; amino acids; salts; miscellaneous suppressant substances; and combinations of any of the foregoing. The improved local anesthetic solution optionally includes one or more additional agents selected from the group consisting of: buffering agents; vasoconstrictors; preservative compounds; stabilizers; contrast media agents; and combinations of any of the foregoing.

Abstract: One aspect of the disclosure relates to the use of derivatives of dichlorophenyl urea for treating cancers.

Abstract: Provided is a method for preparation of a sustained released pharmaceutical composition, wherein an active ingredient and a cellulose derivative dissolved in a lower alkyl alcohol solvent are processed with granulation such that the PEO does not need to be processed with granulation or sizing to achieve uniform drug distribution. Besides, the specific range of the viscosity of the cellulose derivate provides better uniformity to the sustained release pharmaceutical composition derived from the above preparation method.

Abstract: Methods and compositions are provided for increasing the anaerobic working capacity of muscle and other tissues. Also provided are compositions formulated for the sustained release of free beta-alanine. Also provided is a dietary supplement formulated, for example, as a solid food product, an edible suspension, liquid or semi-liquid as described herein.

Abstract: Provided herein are compositions and methods for the treatment and prevention of levodopa-induced dyskinesias (LID). In particular, M4 muscarinic receptor (M4R) positive allosteric modulators (PAMs) are administered to reduce dyskinetic behavior.

Abstract: The invention relates to compounds of natural origin and their pharmaceutically acceptable and active mixture to decrease glucose, cholesterol, uric acid, and body fat the high levels, cytoprotection of damaged organs, activation of metabolism and cell proliferation. It is exemplified with the pharmaceutical composition comprising a pharmaceutically effective amount of the compounds of Formulation I, and its method on in vitro and in vivo systems. Formulation I and its variables can be used to treat hyperglycemia, gout, dyslipidemia, obesity, insulin resistance, diabetes mellitus, diabetes insipidus, type 1 diabetes, type 2 diabetes, microvascular complications, macrovascular complications, lipid disorders, pre-diabetes, arrhythmias, myocardial infarction, renal and pancreatic complications, cardiovascular complications.

Abstract: Provided herein are methods, compositions, and systems for treating mitochondrial disorders (e.g., MERRF, MELAS, Kearns-Sayre syndrome, chronic progressive external ophthalmoplegia, diabetes mellitus and deafness, lactic acidosis, Leber's hereditary optic neuropathy, Wolff-Parkinson-White syndrome, Leigh syndrome, NARP, myoneurogenic gastrointestinal encephalopathy, mitochondrial DNA depletion syndrome) or neurodegenerative diseases (e.g., Alzheimer's disease, Parkinson's disease) by administering aspartate, or an analog or prodrug thereof, or an agent that increases intracellular levels of aspartate. Pharmaceutical compositions and kits for use in treating mitochondrial disorders and neurodegenerative diseases are also described herein. Also provided are methods for treating disease by modulating the redox state of a cell, and methods of treating a proliferative disease by administering a cytosolic aspartate aminotransferase (GOT1) inhibitor.

Abstract: Pharmaceutical compositions with selective tumoricial activity comprising polyunsaturated fatty acids or a pharmaceutically acceptable salt or derivative thereof, in an aqueous solution or emulsion are provided. Methods associated with preparation and use of such compositions and methods to selectively cause tumoricial and/or anti-angiogenic action in a neoplastic region, such as cancer, are also provided.

Abstract: Disclosed herein are methods for (a) inhibiting, reducing, slowing, or preventing, the aging of a subject, (b) for treating, inhibiting, reducing, or preventing an age-related disease in the subject, and/or (c) for increasing the lifespan of the subject which comprise administering to the subject one or more glutamate compounds, such as ?-ketoglutate, and/or one or more glutamate compounds, such as 2-hydroxypentanedioate, and compositions thereof.

Abstract: The present invention relates to combinations and methods for the treatment of neurological disorders related Amyloid beta toxicity and/or neuronal death and/or glucose impaired neuronal metabolism. More specifically, the present invention relates to novel combinatorial therapies of Alzheimer's disease, Alzheimer's disease related disorders, frontotemporal dementia, Parkinson's disease, Lewy body dementia, Huntington's disease, peripheral neuropathies, alcoholism or alcohol withdrawal, neurological manifestations of drug abuse or drug abuse withdrawal, amyotrophic lateral sclerosis, multiple sclerosis, spinal cord injury, epilepsy, traumatic brain injury or brain ischemic events based on baclofen, acamprosate and at least one medium chain triglyceride.

Abstract: Compositions are provided that include having at least 95% by weight of a taxane, or a pharmaceutically acceptable salt thereof, where the particles have a mean bulk density between about 0.050 g/cm3 and about 0.15 g/cm3, and/or a specific surface area (SSA) of at least 18 m2/g, 20 m2/g, 25 m2/g, 30 m2/g, 32 m2/g, 34 m2/g, or 35 m2/g. Methods for making and using such compositions are also provided.

Abstract: Melatonin Agonist, MA-1, is administered at effective doses.

Abstract: The invention provides tricyclic compounds and their use in treating medical disorders, such as obesity. Pharmaceutical compositions and methods of making various tricyclic compounds are provided. The compounds are contemplated to have activity against methionyl aminopeptidase 2.

Abstract: Systems and methods for determining whether a cancer patient may respond to inhibition of RNA polymerase II as a treatment for the patient are provided. Inhibition of RNA polymerase II may be by way of chemotherapy with an agent such as triptolide, an analog of triptolide, or a prodrug form of triptolide. The cancer patient may be a pancreatic cancer patient, an ovarian cancer patient, a gastric cancer patient, or an esophageal cancer patient. The patient may have any cancer in which c-Myc is over-expressed or over-amplified.

Abstract: Provided herein are pharmaceutical compositions comprising a therapeutically effective amount of lipoic acid choline ester or derivatives thereof and a non-aqueous excipient mixed in an aqueous solution. Also provided herein are non-aqueous compositions prepared by mixing the therapeutically effective amount of lipoic acid choline ester and the non-aqueous excipient. The non-aqueous compositions can be further mixed with the aqueous solution.

Abstract: The invention provides compositions and methods for treating cyanide poisoning.

Abstract: A treatment for acid related gastrointestinal disorders. The methods and compounds described include gastric acid secretion inhibitors in combination with alpha lipoic acid (ALA) or related compounds. ALA is not known as a treatment for acid related gastrointestinal disorders; however, when combined with certain compounds used in the treatment of acid related gastrointestinal disorders, ALA significantly improves existing treatments.

Abstract: The present invention describes methods of treating dementia comprising administering an effective daily dose of N-[2-(6-fluoro-1H-indol-3-yl)ethyl]-3-(2,2,3,3-tetrafluoropropoxy)benzylamine to improve or augment the effect of an acetylcholinesterase inhibitor.

Abstract: Compositions and pharmaceutical compositions including one or more selenium-containing COX-2 inhibitors are provided according to aspects of the present invention. Methods of treating a subject having or suspected of having cancer are provided according to aspects of the present invention which include administering a therapeutically effective amount of a pharmaceutical composition including a selenium-containing COX-2 inhibitor.

Abstract: The invention relates to medicine, in particular, to a method for preventing and/or treating a disease associated with a reduced density of interferon receptors, the method comprising administering an effective amount of glutaryl histamine or a pharmaceutically acceptable salt thereof. Said disease may be hepatitis B, herpes, papilloma virus infection, or multiple sclerosis. The invention also relates to a pharmaceutical composition for prevention and/or treatment of diseases associated with a reduced density of interferon receptors, wherein the composition comprises an effective amount of glutaryl histamine or a pharmaceutically acceptable salt thereof. The invention solves a problem of providing a novel agent effective for overcoming a resistance to interferon therapy in diseases selected from the group including hepatitis B, herpes, papilloma virus infection, or multiple sclerosis.

Abstract: The present invention relates to method for treating skin diseases and skin conditions in a subject in need of such treatment, which comprises administering a therapeutically effective amount of a composition comprising ester pro-drugs of [3-(1-(1H-imidazol-4-yl)ethyl)-2-methylphenyl] methanol, or enantiomers thereof, pharmaceutical compositions containing them and their use as pharmaceuticals.

Abstract: The present invention relates to compounds of formula I: and pharmaceutically acceptable salts thereof, pharmaceutical compositions comprising the compounds of formula I, and methods of using said compounds, salts and compositions in the treatment of various disorders associated with CRM1 activity.

Abstract: Pharmaceutical formulations comprise sustained-release zonisamide. Methods of preparing such pharmaceutical formulations involve intermixing zonisamide with a suitable excipient configured to control the dissolution profile of the zonisamide. Methods of treatment involve administering the pharmaceutical formulations to patients in need of such treatment.

Abstract: The present invention relates to topical formulations comprising a compound of the following formula: for treating ocular neovascularization. The Compound-I is present in a solution or a suspension in about 0.005% to about 5.0% w/v, such that the solution or suspension delivers the compound at the posterior segment of the eye for inhibiting VEGF in the retina and/or the choroid.